Research programme: Ebola immunotherapeutics - Emergent BioSolutionsAlternative Names: Anti-Ebola monoclonal antibody - Emergent Biosciences; Ebola hyperimmune product - Emergent BioSciences; Modified vaccinia Ankara Ebola Zaire vaccine; MVA EBOZ; MVA-Ebola vaccine - Emergent BioSciences
Latest Information Update: 22 Jul 2015
At a glance
- Originator Emergent BioSolutions
- Class Monoclonal antibodies; Viral vaccines
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ebola virus infections